Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs

May 10, 2024

https://www.globenewswire.com/news-release/2024/05/10/2879583/0/en/Eterna-Therapeutics-to-Present-at-the-ASGCT-27th-Annual-Meeting-on-Development-of-Beta-2-Microglobulin-Knockout-B2M-KO-iMSC-Line-with-Enhanced-Immunosuppressive-Activity-and-Stealt.html

CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq:ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene + Cell Therapy, taking place in Baltimore, Maryland.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.